Opinion|Videos|September 30, 2024
Safety and Efficacy of HER2-Directed ADCs for NSCLC
Panelists discuss how the selection between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine is guided by findings from pivotal trials like DESTINY-Lung01 and DESTINY-Lung02, real-world patient outcomes compared with clinical trial results, and the management of common treatment-related adverse events associated with these HER2-directed therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What factors guide the choice between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine?
- What key insights emerged from pivotal trials like the phase 2 basket DESTINY-Lung01and DESTINY-Lung02?
- How do real-world patient outcomes compare with those seen in clinical trials?
- What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology
2
Paul Richardson, MD, Calls Mezigdomide “CAR T in a Pill” for Patients With R/R Multiple Myeloma
3
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
4
SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD
5